Centre d'investigations Cliniques Plurithématique, Inserm 1433, Université de Lorraine, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHRU Nancy-Hopitaux de Brabois, 4 rue du Morvan, 54500, Nancy, Vandoeuvre les Nancy, France.
CHRU de Nancy, Inserm U1116, Nancy, France.
Clin Res Cardiol. 2021 Oct;110(10):1554-1563. doi: 10.1007/s00392-021-01830-1. Epub 2021 Mar 8.
Patients with coronary artery disease (CAD) are at increased risk of developing and being hospitalised for heart failure (HFH). However, the risk of HFH versus ischemic events may vary among patients with CAD, depending on whether acute myocardial infarction (MI), left ventricular dysfunction or decompensated HF is present at baseline.
We aim to explore the risk of non-fatal events (HFH, MI, stroke) and subsequent death in 3 landmark trials, COMMANDER-HF, EPHESUS and EXAMINE that, together, included patients with CAD with and without reduced ejection fraction and acute MI.
Events, person-time metrics and time-updated Cox models.
In COMMANDER-HF the event-rate for the composite of AMI, stroke or all-cause death was 13.5 (12.8-14.3) events/100 py. Rates for AMI and stroke were much lower (2.2 [2.0-2.6] and 1.3 [1.1-1.6] events/100 py, respectively) than the rate of HFH (16.9 [16.1-17.9] events/100 py). In EPHESUS, the rates of MI and stroke were also lower than the rate of HFH: 7.2 (6.7-7.8), 1.9 (1.7-2.3), and 10.6 (9.9-11.3) events/100 py, but this was not true for EXAMINE with 4.4 (4.0-4.9), 0.7 (0.6-0.9), and 2.4 (2.0-2.7) events/100 py, respectively. In all 3 trials, a non-fatal event (HFH, MI or stroke) during follow-up doubled the risk of subsequent mortality. This most commonly followed a HFH.
A first or recurrent HFH is common in patients with CAD and AMI or HFrEF and indicates a poor prognosis. Preventing the development of heart failure after AMI and control of congestion in patients with CAD and HFrEF are key unmet needs and therapeutic targets.
ClinicalTrials.gov Identifier: NCT01877915. URL: https://clinicaltrials.gov/ct2/show/NCT01877915 .
患有冠状动脉疾病 (CAD) 的患者发生心力衰竭 (HFH) 和住院的风险增加。然而,CAD 患者发生 HFH 与缺血性事件的风险可能因基线时是否存在急性心肌梗死 (MI)、左心室功能障碍或失代偿性 HF 而有所不同。
我们旨在探索 3 项标志性试验(COMMANDER-HF、EPHESUS 和 EXAMINE)中无致命事件(HFH、MI、中风)和随后死亡的风险,这些试验共同纳入了有和无射血分数降低的 CAD 患者以及急性 MI 患者。
事件、人时指标和时间更新的 Cox 模型。
在 COMMANDER-HF 中,AMI、中风或全因死亡的复合事件发生率为 13.5(12.8-14.3)/100 人年。AMI 和中风的发生率要低得多(分别为 2.2 [2.0-2.6] 和 1.3 [1.1-1.6]/100 人年),而 HFH 的发生率为 16.9(16.1-17.9)/100 人年。在 EPHESUS 中,MI 和中风的发生率也低于 HFH:7.2(6.7-7.8)、1.9(1.7-2.3)和 10.6(9.9-11.3)/100 人年,但在 EXAMINE 中并非如此,发生率分别为 4.4(4.0-4.9)、0.7(0.6-0.9)和 2.4(2.0-2.7)/100 人年。在所有 3 项试验中,随访期间发生非致命事件(HFH、MI 或中风)会使随后死亡的风险增加一倍。这通常紧随 HFH 之后发生。
CAD 患者伴或不伴 AMI 或射血分数保留的心力衰竭(HFpEF)首次或复发 HFH 很常见,提示预后不良。预防 AMI 后心力衰竭的发生和控制 CAD 伴 HFpEF 患者的充血是未满足的关键需求和治疗目标。
临床试验.gov 标识符:NCT01877915。网址:https://clinicaltrials.gov/ct2/show/NCT01877915。